Peptest has been described as a ‘good first-line diagnostic procedure to use in reflux sufferers to confirm the presence of reflux’ in the Journal of Gastrointestinal and Liver Diseases.
The research paper published in the Journal is entitled ‘Validation of Peptest in Patients with Gastro-Esophageal Reflux Disease and Laryngopharyngeal Reflux Undergoing Impedance Testing’.
The aim of this study was to validate the use of Peptest to reliably diagnose reflux in patients with gastro-oesophageal reflux disease (GERD/GORD) and laryngopharyngeal reflux disease (LPR) diagnosed with multichannel intraluminal impedance/ pHmetry (MII-pH).
MII-pH involves a small probe inserted through your nostril and positioned above the lower oesophageal sphinter (LOS) and determines the physical characteristics of refluxate (liquid, gas, or mixed).
20 reflux patients were recruited of whom 10 had classical GERD/GORD and 10 had LPR. All patients underwent MII-pH and provided expectorated saliva samples when a MII-pH reflux event was observed, or reflux symptoms were experienced, and all were tested for the presence of pepsin using the Peptest.
According to the paper, if a patient had reflux symptoms then Peptest was 68.3 per cent more likely to objectively identify them and therefore excluded the need for an expensive and invasive test such as a MII-pH or endoscopy.
Likewise, if someone had an objective reflux event, then the Peptest™ was 67.5 per cent more likely to identify it
Researchers conclude that based on a number of studies, Peptest might be used as a first line diagnostic tool for reflux patients without the need to undergo invasive diagnostic tests in the majority of patients.